• Featured image co-culture assay for paper Grobben et al (2021) Frontiers in Immunology

Tryptophan-metabolizing enzymes in cancer immunology

January 28th, 2021|

January 28, 2021: A new article on the role of tryptophan-metabolizing enzymes in cancer immunology is now online in Frontiers in Immunology (Grobben et al., 2021). The figure shows a co-culture assay of IDO1-overexpressing [...]

NTRC’s key TTK kinase inhibitor patent granted in US

September 25th, 2017|

Oss, September, 19th , 2017 – NTRC, a biopharmaceutical company focused on the discovery and development of innovative precision medicines for the treatment of cancer, today announced that the United States Patent and Trademarks Office [...]

NTRC publishes an association of CTNNB1 mutant status and increased cancer cell line sensitivity to TTK inhibitors

July 28th, 2017|

Normal 0 21 false false false NL X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:Standaardtabel; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";} Oss, July, 27th, 2017 [...]

NTRC expands Oncolines™ cell line panel to 102 cell lines

June 23rd, 2017|

Oss, June 22nd 2017 – Today NTRC has launched an expansion of its Oncolines™ cancer cell line panel, from 66 to 102 cell lines. Oncolines™ are proliferation assays on a panel of genetically well-characterized cancer [...]

Structural insight into the function of TDO in healthy aging

December 23rd, 2016|

Oss, Groningen, December, 23rd, 2016 – Researchers from the European Research Institute for the Biology of Aging (ERIBA) University of Groningen, the Netherlands) in collaboration with the Netherlands Translational Research Center B.V. have identified an [...]

NTRC presents on TTK kinase program at AACR conference

April 8th, 2016|

Oss, April, 8th, 2016 – At the AACR 2016 conference, to be held in New Orleans next week, Jos de Man, Senior Investigator Chemistry at NTRC, will present on the unique binding mode of NTRC’s [...]

NTRC presents at Discovery on Target conference in Boston

August 31st, 2015|

Guido Zaman and Suzanne van Gerwen will attend the Discovery on Target conference, that will be held in Boston (USA) from September 21st to 24th. On Thursday September 24th at 12.10 p.m., Guido Zaman will [...]

Whole genome doubling causes multidrug resistance

July 8th, 2015|

Oss, July 7th, 2015 – In a new study in Cell Cycle, researchers from the Max Planck Institute and NTRC show that doubling of the whole genome of human cancer cells provides resistance to a [...]

NTRC launches assay for mouse IDO1 and mouse TDO activity

January 15th, 2015|

Cancer immunotherapy aims at the stimulation of the body’s immune system to fight cancer. The T-cell immune response against cancer cells is dampened by the activity of the enzymes indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase [...]

NTRC starts at the Life Sciences Park Oss

June 6th, 2012|

Oss – 6 June 2012 - Netherlands Translational Research Center B.V. (NTRC) starts operations at the Life Sciences Park Oss, after successful closing its first round of financing. With the financial support of the Brabant [...]